Whales with a lot of money to spend have taken a noticeably bullish stance on Moderna.
Looking at options history for Moderna MRNA we detected 10 trades.
If we consider the specifics of each trade, it is accurate to state that 70% of the investors opened trades with bullish expectations and 30% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $255,590 and 8, calls, for a total amount of $534,948.
Projected Price Targets
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $85.0 to $150.0 for Moderna over the recent three months.
Insights into Volume & Open Interest
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Moderna's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Moderna's substantial trades, within a strike price spectrum from $85.0 to $150.0 over the preceding 30 days.
Moderna 30-Day Option Volume & Interest Snapshot
Largest Options Trades Observed:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MRNA | PUT | TRADE | BULLISH | 01/16/26 | $14.8 | $14.6 | $14.6 | $85.00 | $211.7K | 424 | 145 |
| MRNA | CALL | SWEEP | BULLISH | 05/17/24 | $17.05 | $16.95 | $17.0 | $85.00 | $164.9K | 98 | 97 |
| MRNA | CALL | TRADE | BEARISH | 06/20/25 | $11.2 | $10.95 | $11.0 | $150.00 | $132.0K | 116 | 0 |
| MRNA | CALL | SWEEP | BULLISH | 05/17/24 | $8.2 | $8.05 | $8.2 | $99.00 | $67.2K | 0 | 109 |
| MRNA | PUT | SWEEP | BULLISH | 06/21/24 | $4.2 | $3.85 | $3.85 | $90.00 | $43.8K | 1.2K | 151 |
About Moderna
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Following our analysis of the options activities associated with Moderna, we pivot to a closer look at the company's own performance.
Present Market Standing of Moderna
- Currently trading with a volume of 1,387,245, the MRNA's price is up by 2.33%, now at $103.77.
- RSI readings suggest the stock is currently is currently neutral between overbought and oversold.
- Anticipated earnings release is in 10 days.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Moderna with Benzinga Pro for real-time alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
